|
|
|
|
|
| Spinelli,G.A.; Felipe,C.R.; Machado,P.G.; Garcia,R.; Casarini,D.E.; Moreira,S.R.; Park,S.I.; Tedesco-Silva Jr.,H.; Medina-Pestana,J.O.. |
| The influence of drug concentrations on the development of persistent posttransplant hyperlipidemia was investigated in 82 patients who received cyclosporin A (CsA) and prednisone plus sirolimus (SRL) (52) or azathioprine (AZA) (30) during the first year after transplantation. Blood levels of CsA and SRL, daily doses of AZA and prednisone, and cholesterol, triglyceride, and glucose concentrations were determined during each visit (pretransplant and 30, 60, 90, 120, 180, and 360 days posttransplant). Persistent hyperlipidemia was defined as one-year average steady-state cholesterol (CavCHOL) or triglyceride (CavTG) concentrations above 240 and 200 mg/dL, respectively. Mean cholesterol and triglyceride concentrations increased after transplantation (P <... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hyperlipidemia; Cholesterol; Triglyceride; Kidney transplantation; Cyclosporin A; Sirolimus. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000100003 |
| |
|
|
| Garcia,R.; Machado,P.G.; Felipe,C.R.; Park,S.I.; Spinelli,G.A.; Franco,M.F.; Tedesco-Silva Jr.,H.; Medina-Pestana,J.O.. |
| Chronic allograft nephropathy is among the major causes of graft loss even in low-risk kidney transplant recipients and correlates with acute nephrotoxic events during the first year post-transplant. Therefore, calcineurin inhibitor-free regimens may improve patient and graft survival among recipients of living-related kidney transplants. To confirm this hypothesis, we evaluated the efficacy and safety of two calcineurin inhibitor-free regimens in 92 low-risk recipients of one-haplotype living-related kidney transplants. Immunosuppression consisted of tacrolimus, azathioprine and prednisone (group I, GI, N = 38), 2 doses of daclizumab, mycophenolate mofetil (MMF), and prednisone (GII, N = 33) and 2 doses of daclizumab, MMF, sirolimus and prednisone (GIII,... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Tacrolimus; Mycophenolate mofetil; Sirolimus; Kidney transplantation; Acute rejection; Clinical trial. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000400003 |
| |
|
|
| Machado,P.G.P.; Felipe,C.R.; Park,S.I.; Garcia,R.; Moreira,S.; Casarini,D.; Franco,M.; Alfieri,F.; Tedesco-Silva Jr.,H.; Medina-Pestana,J.O.. |
| The use of sirolimus (SRL) in combination with full doses of cyclosporin A (CsA) results in reduced one-year kidney allograft function, which is associated with shorter long-term allograft survival. We determined the effect of reduced CsA exposure on graft function in patients receiving SRL and prednisone. Ninety recipients of living kidney transplants receiving SRL (2 mg/day, po) were compared to 35 recipients receiving azathioprine (AZA, 2 mg kg-1 day-1, po). All patients also received CsA (8-10 mg kg-1 day-1, po) and prednisone (0.5 mg kg-1 day-1). Efficacy end-point was a composite of biopsy-confirmed acute rejection, graft loss, or death at one year. Graft function was measured by creatinine, creatinine clearance, and graft function deterioration... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Sirolimus; Cyclosporine; Graft function; Immunosuppression; Kidney transplantation. |
| Ano: 2004 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000900004 |
| |
|
|
| Gadioli,A.L.N.; Nogueira,B.V.; Arruda,R.M.P.; Pereira,R.B.; Meyrelles,S.S.; Arruda,J.A.; Vasquez,E.C.. |
| The objective of the present study was to assess the effects of the immunosuppressant rapamycin (Rapamune®, Sirolimus) on both resistance vessel responsiveness and atherosclerosis in apolipoprotein E-deficient 8-week-old male mice fed a normal rodent diet. Norepinephrine (NE)-induced vasoconstriction, acetylcholine (ACh)- and sodium nitroprusside (SNP)-induced vasorelaxation of isolated mesenteric bed, and atherosclerotic lesions were evaluated. After 12 weeks of orally administered rapamycin (5 mg·kg-1·day-1, N = 9) and compared with untreated (control, N = 9) animals, rapamycin treatment did not modify either NE-induced vasoconstriction (maximal response: 114 ± 4 vs 124 ± 10 mmHg, respectively) or ACh- (maximal response: 51 ± 8 vs 53 ± 5%, respectively)... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Rapamycin; Sirolimus; Atherosclerosis; Vascular responsiveness; Apolipoprotein E; Mice. |
| Ano: 2009 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009001200012 |
| |
|
|
|
